Toronto, Ontario (22 August 2025) – TheNewswire - Helix BioPharma Corp. (TSX: “HBP”, OTC: “HBPCF”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a near future where today’s hard-to-treat cancers are vincible, is pleased to announce that the Company has closed its non-brokered private placement (the “Private Placement”) of 2,222,333 common shares of the Company (the “Common Shares”) at a price of $0.75 per Common Share for gross proceeds of $1,666,750.00 (“the Offering”).  The Company will launch the next Private Placement once new price protection approval has been granted by the TSX.

 

Following the closure of a private placement of $3,000,000 announced by the Company in its press release dated January 9, 2025,i this Private Placement marks the second phase in Helix’s bridge financing strategy, as the Company advances toward securing a larger institutional investment. Helix intends to invest the net proceeds of the Private Placement toward near-term development activities and working capital, while building on the Company’s active and constructive discussions with institutional investors, which are expected to culminate in a larger financing round that will support Helix’s long-term strategic plan and uplisting on NASDAQ. The Offering is subject to final approval of the Toronto Stock Exchange, and the Common Shares are subject to a hold period of four months and one day expiring on December 23, 2025, in accordance with applicable securities laws. In connection with the closing of the Offering, the Company will pay finders’ fees to certain eligible finders.

 

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws unless an exemption from such registration is available.

 

—ENDS—

   

About Helix BioPharma Corp.

Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today’s hardest-to-treat cancers. The Company’s pipeline is led by Tumor Defense Breaker™ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today’s front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix’s next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery. The Company also advances two pre-IND candidates: (i) LEUMUNA™, an oral immune checkpoint modulator aimed at achieving durable remission in post-transplant leukemia relapse, and (ii) GEMCEDA™, a first-in-class oral gemcitabine prodrug with bioavailability on a par with IV, designed to expand treatment options for advanced cancers.

 

Helix is listed on TSX (HBP), OTC PINK (HBPCD), and FWB (HBP0). For more information, please visit: https://www.helixbiopharma.com/

 

For more information, please contact:

Helix BioPharma Corp.

Bay Adelaide Centre - North Tower

40 Temperance Street, Suite 2

Toronto, ON M5H 0B4

Tel: +1 857 208 7687

Thomas Mehrling, CEO

corporate@helixbiopharma.com

  

Forward-Looking Statements and Risks and Uncertainties

 

This news release contains forward-looking statements and information (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities laws. Forward-looking statements are statements and information that are not historical facts but instead include financial projections and estimates, statements regarding plans, goals, objectives, intentions and expectations with respect to the Company’s future business, operations, research and development, including the Company’s activities relating to Tumor Defense Breaker™ L-DOS47, LEUMUNA™ and GEMCEDA™. These statements use terms like “estimates,” “expects,” “will,” and similar language indicating future events, or the negative thereof or any other comparable terminology referring to future events or results. 

 

However, forward-looking statements are subject to risks and uncertainties beyond Helix’s control, which may lead to actual results differing materially from those anticipated. These risks and uncertainties include, but are not limited to, risks relating to Helix’s financial condition, including (a) lack of significant revenues to date and reliance on equity and other financing; (b) business, including its stage of development, government regulation, development success of and market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of Helix to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Forward-looking statements reflect the management’s current beliefs and are based on information available to the management on the date of this news release, and the Company does not assume the obligation to update any forward-looking statement should those beliefs change, except as required by law. Further information regarding these risks and uncertainties can be found in Helix’s periodic reports and information forms on the Company’s SEDAR+ profile at www.sedarplus.ca.

  

i https://www.helixbiopharma.com/fy2025/helix-biopharma-corp-announces-closing-of-private-placement-of-common-shares-3/